Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Morphic Holding, Inc. (MORF)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/12/2023
8-K
Quarterly results
09/26/2023
8-K
Quarterly results
08/03/2023
8-K
Quarterly results
Docs:
"
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 -Reported positive topline results from EMERALD-1study of MORF-057 in ulcerative colitis-
"
05/03/2023
8-K
Quarterly results
04/25/2023
8-K
Quarterly results
04/25/2023
8-K
Quarterly results
02/23/2023
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23-
"
02/13/2023
8-K
Quarterly results
01/20/2023
8-K
Termination of a Material Definitive Agreement Interactive Data
11/02/2022
8-K
Quarterly results
10/24/2022
8-K
Quarterly results
08/03/2022
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team
"
06/21/2022
8-K
Quarterly results
06/09/2022
8-K
Quarterly results
05/12/2022
8-K
Quarterly results
05/04/2022
8-K
Quarterly results
03/15/2022
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/24/2022
8-K
Quarterly results
11/04/2021
8-K
Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs:
"
Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22
"
08/23/2021
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
"
08/04/2021
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs:
"
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22
"
07/09/2021
8-K
Other Events, Financial Statements and Exhibits
Docs:
"
###
"
06/21/2021
8-K
Quarterly results
06/01/2021
8-K
Quarterly results
04/29/2021
8-K
Quarterly results
03/03/2021
8-K
Quarterly results
03/01/2021
8-K
Quarterly results
01/05/2021
8-K
Quarterly results
12/04/2020
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
"
11/09/2020
8-K
Quarterly results
Docs:
"
Press release issued by Morphic Holding, Inc. regarding its financial results for the quarter ended September 30, 2020
"
09/23/2020
8-K
Quarterly results
08/25/2020
8-K
Quarterly results
08/10/2020
8-K
Quarterly results
06/19/2020
8-K
Submission of Matters to a Vote of Security Holders
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy